Ulanqab Kema Makes Debut at CPHI South-East Asia 2026, Showcasing High-Quality Pharmaceutical Excipients for Southeast Asian Market
Bangkok, Thailand – July 2026 From July 8 to 10, 2026, CPHI South-East Asia 2026 was held at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand--2. As the most influential pharmaceutical trade show in Southeast Asia, this year's event brought together over 400 exhibitors from more than 70 countries and regions, along with over 10,000 professional visitors-5-23. Ulanqab Kema New Material Co., Ltd. ("Kema New Material") made its debut at the exhibition with its full range of pharmaceutical-grade PVP (polyvinylpyrrolidone) core products, presenting the quality, strength, and green manufacturing advantages of Chinese pharmaceutical excipients to the global pharmaceutical industry as an innovative fine chemical enterprise from Inner Mongolia.
Founded in 2017 and located in the Mengwei New Material Industrial Park in Chayouhouqi, Ulanqab, Inner Mongolia, Kema New Material is a high-tech enterprise specializing in the R&D, production, and sales of N-vinylpyrrolidone (NVP) and polyvinylpyrrolidone (PVP) series products. At the exhibition, the company highlighted six core product categories: pharmaceutical-grade PVP K17, K30, K90, crospovidone, povidone-iodine, and high-purity NVP monomer, offering integrated solutions for pharmaceutical applications including tablet binding, disintegration, coating, formulation, and oral liquid clarification. The flagship product, pharmaceutical-grade PVP K30, became a centerpiece of attention with its four core advantages-ultra-low moisture, high purity, low heavy metal content, and strong dissolution stability-meeting the production requirements for oral solid dosage forms, injections, povidone-iodine, biological dressings, and more.
Throughout the exhibition, Kema's professional technical and foreign trade teams provided one-on-one consultations, elaborating on product specifications from multiple dimensions including production processes, quality control, compliance certification, customized mass production, and cross-border supply chain capabilities. The company highlighted its closed-loop clean production processes, full-process dust-free refining workshops, and comprehensive testing systems, aligning with the industry trends of green and low-carbon development, strict impurity control, and stable batch supply. Dozens of cooperation intentions were secured on-site, covering three partnership models: long-term raw material supply, overseas regional distribution, and high-end customized R&D.
A company representative stated: "CPHI brings together the core resources of the global pharmaceutical industry chain and serves as a bridge for Chinese fine chemical enterprises to reach the world. As a local enterprise rooted in Inner Mongolia, we aim to leverage our high-quality pharmaceutical-grade PVP products to let the global market see the strength of manufacturing from northern China and domestic excipients."
This debut at CPHI South-East Asia marks the official launch of Kema New Material's strategic expansion into the Southeast Asian market. Looking ahead, the company will continue to increase R&D investment in new pharmaceutical materials, refine its product portfolio, expand its global distribution network, and drive quality upgrades through technological innovation, striving to become a leading domestic manufacturer of pyrrolidone series new materials.